http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2121344-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8be5467238d2f02d35f1fcbe430ecdaf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate | 1991-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1998-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be01c737886305830d40784c8f30ff97 |
| publicationDate | 1998-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2121344-C1 |
| titleOfInvention | Medicinal form of biphase effect exhibiting releasing for lipophilic preparations and a method of its preparing |
| abstract | FIELD: medicine, pharmacy. SUBSTANCE: medicinal form is used by oral route and consists of two phases: phase of nonprolonged releasing and phase of prolonged releasing the components. Form has C 12 -C 24 -fatty acid and pharmaceutically active lipophilic substance. Phase of nonprolonged releasing has part of fatty acid and phase of prolonged releasing has the rest part of fatty acid and at least part of pharmaceutically active substance. Mass ratio of fatty acid and an active substance is from 10:1 to 1:1. C 12 -C 24 -fatty acid is an oleic and/or linolenic acid. Pharmaceutically active lipophilic substance is a propranolol, verapamil, nifedipin, diltiazem, methoprolol, nicardipine and/or labetolol. New medicinal form promotes an absorption redistribution of drug from portal circulatory system to lymphatic system and excludes drug metabolism at its the first passing through the liver. Drug bioavailability is enhanced. EFFECT: enhanced effectiveness of medicinal form. 13 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2457821-C2 |
| priorityDate | 1990-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 262.